The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase

Jennie O'Loughlin, Silvia Napolitano, Fahad Alkhathami, Cillian O'Beirne, Daniel Marhöfer, Megan O'Shaughnessy, Orla Howe, Matthias Tacke, Marina Rubini

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Antibiotic resistance is a growing problem for public health and associated with increasing economic costs and mortality rates. Silver and silver-related compounds have been used for centuries due to their antimicrobial properties. In this work, we show that 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene silver(I) acetate/NHC*-Ag-OAc (SBC3) is a reversible, high affinity inhibitor of E. coli thioredoxin reductase (TrxR; Ki=10.8±1.2 nM). Minimal inhibition concentration (MIC) tests with different E. coli and P. aeruginosa strains demonstrated that SBC3 can efficiently inhibit bacterial cell growth, especially in combination with established antibiotics like gentamicin. Our results show that SBC3 is a promising antibiotic drug candidate targeting bacterial TrxR.

Original languageEnglish
Pages (from-to)1093-1098
Number of pages6
JournalChemBioChem
Volume22
Issue number6
DOIs
Publication statusPublished - 16 Mar 2021

Keywords

  • antibiotic resistance
  • antibiotics
  • inhibitors
  • NHC-metal complexes
  • thioredoxin reductase

Fingerprint

Dive into the research topics of 'The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase'. Together they form a unique fingerprint.

Cite this